Medicare Advantage Accelerates Claims Approval for Exoskeleton Devices
Lifeward reports accelerated Medicare Advantage claims approvals for ReWalk 7 Exoskeleton, improving access and payment timelines in 2025.
Lifeward reports accelerated Medicare Advantage claims approvals for ReWalk 7 Exoskeleton, improving access and payment timelines in 2025.
CMS approves New Technology Add-on Payment for Renata Medical's Minima stent, enabling enhanced reimbursement for innovative pediatric congenital heart disease treatment.
Nexalin supports bipartisan Health Tech Investment Act to expand Medicare reimbursement for FDA-approved AI medical devices, aiding innovation in mental health treatment.
The Health Tech Investment Act aims to create a consistent Medicare payment system for FDA-approved AI medical devices, enhancing patient access and improving healthcare outcomes.